The Secret to Making Peptide Pills Work: A Specific Bond Shape That Helps Peptides Cross the Gut Wall | Research

The takeaway

N-methylated cis-peptide bonds in cyclic peptides correlate with increased intestinal permeability, potentially providing a structural blueprint for designing oral peptide drugs.

cis-bond = gut permeability
The majority of permeable cyclic peptides in this study contained an N-methylated cis-peptide bond — the same structural feature found in cyclosporine A, one of the few orally available peptide drugs.

What the researchers found

N-methylated cis-peptide bonds appear to be a key structural feature that enables cyclic peptides to cross the intestinal barrier. Among 13 N-methylated cyclic pentaalanine peptides tested, those containing cis-peptide bonds showed the highest intestinal permeability in Caco-2 cell models. This structural feature is shared by known orally available cyclic peptides like cyclosporine A. The study also found that enantiomeric pairs (mirror-image peptides) had different permeabilities, strongly suggesting that absorption involves specific carrier-mediated transport pathways rather than simple passive diffusion, especially for polar peptide scaffolds.

Why it matters

The biggest obstacle to oral peptide drugs is their inability to cross the intestinal wall — they get degraded by digestive enzymes and can't penetrate the gut lining. Identifying specific structural features (like cis-peptide bonds) that enable gut absorption is critical for designing the next generation of oral peptide therapeutics. If medicinal chemists can incorporate these features into therapeutic peptides, it could transform peptide drugs from injection-only medications into pills — dramatically improving patient compliance and accessibility.

The numbers in context

13 cyclic pentapeptides tested · Caco-2 and PAMPA permeability assays · cis-peptide bond identified as key feature · Enantiomeric differential permeability observed

How the study worked

Researchers synthesized 13 N-methylated cyclic pentaalanine peptides derived from the cyclo(-D-Ala-Ala4-) template. Intestinal permeability was measured using Caco-2 cell monolayers (a standard model for intestinal epithelium) and PAMPA (parallel artificial membrane permeability assay). Structural conformations were characterized to correlate backbone geometry with permeability. Enantiomeric pairs were compared to distinguish passive transport from carrier-mediated uptake.

Who was studied

Not applicable — in vitro permeability study using 13 synthetic cyclic peptides in Caco-2 and PAMPA models

What this study cannot tell us

This is an in vitro study using cell models — actual in vivo oral bioavailability may differ due to additional factors like enzymatic degradation, bile salt interactions, and first-pass liver metabolism. Only 13 peptides from a single template were tested, limiting the generalizability of the structural rules. The peptides had generally moderate to low permeability, with only a few reaching the paracellular marker level. The mechanistic basis for how cis-peptide bonds promote permeability remains hypothetical.

How to read the evidence

This is an in vitro structure-permeability study using established intestinal absorption models (Caco-2, PAMPA). The correlation between cis-peptide bonds and permeability is observational, and the number of peptides tested is small. However, the consistency with known oral peptides (cyclosporine A) strengthens the hypothesis.

When this study was published

Published in 2015, this study contributed to the foundational understanding of oral peptide bioavailability. The structural rules identified here have since informed ongoing efforts to design orally available peptide drugs, a field that continues to advance rapidly.

The bigger picture

Oral peptide drug delivery is considered a "holy grail" of pharmaceutical science. Currently, most peptide drugs (insulin, semaglutide injection, GLP-1 agonists) require injection because they can't survive the digestive tract. While oral semaglutide exists, it requires special formulation and fasting conditions. Understanding the fundamental structural rules that allow peptides like cyclosporine A to be orally available could enable systematic design of oral peptide therapeutics across many disease areas.

Questions still open

Can the cis-peptide bond feature be incorporated into therapeutic peptides without compromising their biological activity?
Which carrier-mediated transport pathways are responsible for taking up peptides with cis-bonds, and can they handle peptides of clinically relevant sizes?
Do these in vitro permeability rules hold up in vivo, where additional barriers like enzymatic degradation and hepatic first-pass metabolism come into play?

Common questions

Why can't most peptide drugs be taken as pills?

Peptides face two major hurdles when swallowed: digestive enzymes in the stomach and intestine break them down, and even if they survive, they're usually too large and polar to cross the intestinal wall into the bloodstream. This study identifies a specific structural feature that helps peptides overcome the absorption barrier.

What is a cis-peptide bond?

In most peptides, the bonds between amino acids are in a 'trans' orientation — stretched out. A 'cis' bond means the chain folds back on itself at that point, creating a kink. When combined with N-methylation (adding a methyl group), this kink appears to help the peptide adopt a shape that can cross the intestinal wall, possibly by interacting with transport proteins.

Read the original research

cis-Peptide Bonds: A Key for Intestinal Permeability of Peptides? .

Chemistry (Weinheim an der Bergstrasse, Germany), 21(43), 15148-52

View on PubMed ↗Publisher’s paper ↗

Citation

Marelli, Udaya Kiran; Ovadia, Oded; Frank, Andreas Oliver; Chatterjee, Jayanta; Gilon, Chaim; Hoffman, Amnon; Kessler, Horst. (2015). cis-Peptide Bonds: A Key for Intestinal Permeability of Peptides? .. Chemistry (Weinheim an der Bergstrasse, Germany), 21(43), 15148-52. https://doi.org/10.1002/chem.201501600